Skip to content

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

  • Home
  • About
    • Home
    • Lung Cancer
    • Non-Small Cell Lung Cancer
Breast Cancer Cancer Head and Neck Cancer Non-Small Cell Lung Cancer Prostate Cancer Stomach Cancer

Docetaxel is a Microtubule Depolymerization Inhibitor for Solid Tumour Research

Louis Gilman November 9, 2023

Microtubules are a component of the cytoskeleton. Microtubules are found in eukaryotic cells and are formed by the polymerization of a dimer of two globular proteins, alpha and beta tubulin.…

Lung Cancer Non-Small Cell Lung Cancer

Osimertinib (AZD9291) is an Orally Active EGFR Inhibitor for Lung Cancer Research

Louis Gilman August 31, 2023

EGFR-mutated (EGFRm+) non-small cell lung cancer (NSCLC) is a major clinical problem. Tyrosine kinase inhibitors (TKIs) have precision therapeutic implications for advanced NSCLC. However, common EGFR mutations, such as EGFRL858R,…

Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Non-Small Cell Lung Cancer

Afatinib is an Orally Active EGFR/HER2 Dual Inhibitor for Cancer Research

Louis Gilman August 17, 2023

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). These structurally related receptors…

Breast Cancer Cancer HER2+ Breast Cancer Lung Cancer Non-Small Cell Lung Cancer

Capivasertib (AZD5363) is an Orally Active and Potent Pan-AKT Kinase Inhibitor

Louis Gilman May 4, 2023

ATR kinase is a key component of the DNA damage response pathway. Additionally, it plays a critical role in maintaining genome stability. Ceralasertib (AZD6738) is a potent inhibitor of ATR…

Cancer Large Cell Lung Cancer Lung Cancer Non-Small Cell Lung Cancer

RMC-6291 is an Orally Active and Covalent KRASG12C Inhibitor for Solid Tumor Research

Louis Gilman April 26, 2023

KRAS  plays a critical role in regulating cell growth and division. KRAS mutations are common in many types of solid tumors, including lung, colon, and pancreatic cancers, and are associated…

Bladder Cancer Melanoma Mesothelioma Non-Small Cell Lung Cancer Squamous Carcinoma

Obrindatamab is a Humanized Anti-B7-H3/CD3 Bispecific Antibody for Cancer Research

Louis Gilman March 30, 2023

B7-H3 (CD276) is a T cell co-stimulator and co-suppressor molecule. Specifically, B7-H3 plays an important role in tumor cell apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and escape from immune surveillance.…

Cancer Colon Cancer Colorectal Cancer Lung Cancer Non-Small Cell Lung Cancer

Izalontamab (SI-B001) is a Bispecific Anti-EGFR/HER3 mAb for Cancer Research

Louis Gilman March 15, 2023

EGFR (epidermal growth factor receptor) is a member of the ErbB receptor family1. Besides, EGFR is a common therapeutic strategy in epithelioma such as lung adenocarcinoma, colon cancer, head and…

Cancer Non-Small Cell Lung Cancer NSCLC

Opnurasib (JDQ-443) is an Orally Active KRAS G12C Inhibitor

Louis Gilman February 21, 2023

Kirsten rat sarcoma (KRAS) is a member of the RAS family. KRAS is a key regulator of signaling pathways responsible for cell proliferation, differentiation, and survival. KRAS mutations are genetic…

Breast Cancer Non-Small Cell Lung Cancer

OTS193320 is a SUV39H2 Methyltransferase Activity Inhibitor

Louis Gilman January 5, 2023

SUV39H2 is a histone lysine-specific methyltransferase. Specifically, SUV39H2 introduced H3K9me3 to induce transcriptional inhibition. This plays a key role in heterochromatin maintenance, DNA repair, more recently, carcinogenesis. Besides, the genetic…

Lung Cancer Non-Small Cell Lung Cancer

Adagrasib (MRTX849), a Potent KRAS G12C Inhibitor for KRAS G12C-mutated Locally Advanced or Metastatic NSCLC Research

Louis Gilman December 14, 2022

On December 12, 2022, FDA granted accelerated approval to Adagrasib (Krazati), for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. In 2021, FDA approved the selective KRASG12C mutant…

Posts navigation

1 2 … 7

Next Page »

Recent Posts

  • Erlotinib is an EGFR TKI for NSCLC and Pancreatic Cancer Research
  • Parsaclisib is an Orally Active PI3Kδ Inhibitor for B-cell Malignancies Research
  • Nilotinib is an Orally Active Bcr-Abl Tyrosine Kinase Inhibitor for CML Research
  • Temsirolimus is an mTOR Inhibitor for Kinds of Cancers Research
  • Toripalimab is an Anti-tumor PD-1 Antibody for Nasopharyngeal Carcinoma Research

Archives

  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019

Categories

  • Abdominal Aortic Aneurysm
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Adenoid Cystic Carcinoma
  • Adenomyosis
  • Adrenocortical carcinoma
  • Adult T-cell leukemia/lymphoma
  • Anti-angiogenic
  • anti-inflammatory
  • antioxidant
  • autoimmune disease
  • B-cell malignancies
  • Bladder Cancer
  • Bone Cancer
  • Brain Cancer
  • Breast Cancer
  • Cancer
  • Cancer Metastases
  • Castration Resistant Prostate Cancer
  • ccRCC
  • Cervical Cancer
  • Cervix Cancer
  • Chemotherapy
  • Chemotherapy Side Effects
  • Cholangiocarcinoma
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colon Adenocarcinoma
  • Colon Cancer
  • Colorectal Cancer
  • Colorectal Cancer
  • Endometrial Adenocarcinoma
  • Endometrial Cancer
  • ER+ Breast Cancer
  • Esophageal Squamous Cell Carcinoma
  • Esophagus Cancer
  • Ewing's Sarcoma
  • Fibrosarcoma
  • Follicular Lymphoma
  • Gastric Adenocarcinoma
  • Gastric Cancer
  • Gastrointestinal Stromal Tumor
  • Glioblastoma
  • Glioblastoma Multiforme
  • Gliocytoma
  • Glioma
  • Head & Neck Cancer
  • Head and Neck Cancer
  • Hematologic Neoplasms
  • Hematological Malignancies
  • Hepatocellular carcinoma
  • HER2+ Breast Cancer
  • Hodgkin Lymphoma
  • HPV
  • HSV-1
  • Idiopathic Pulmonary Fibrosis
  • Kaposi's Sarcoma
  • Kidney Cancer
  • Large B Cell Lymphoma
  • Large B-cell Lymphoma
  • Large Cell Lung Cancer
  • Leukemia
  • Liver Cancer
  • Lung Adenocarcinoma
  • Lung Cancer
  • Lymphoma
  • Malaria
  • Mantle Cell Lymphoma
  • Medullary Thyroid Carcinoma
  • Medulloblastoma
  • Medulloblastomas
  • Megakaryoblastic Leukemia
  • Melanoma
  • Mesothelioma
  • Metabolism
  • Metabolism-related diseases
  • Metastatic Castration-resistant Prostate Cancer
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome
  • Myeloma
  • Nasopharyngeal Carcinoma
  • Neoplasms
  • Neuroblastoma
  • Neuroendocrine Tumors
  • Neuropathy
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • NSCLC
  • NUT midline carcinoma
  • Obesity
  • Oesophageal Cancer
  • Oral Carcinoma
  • Osteosarcoma
  • Ovary Cancer
  • Pancreas Cancer
  • Pancreatic cancer
  • Pancreatic cancer
  • Pancreatic Ductal Adenocarcinoma
  • Ph+ ALL
  • Philadelphia-positive Leukemias
  • Plasmacytoma
  • Prostate Cancer
  • PROTAC
  • Renal Carcinoma
  • Sarcoma
  • Skin Cancer
  • Small Cell Lung Cancer
  • Soft Tissue Tumor
  • Solid Tumors
  • Squamous Carcinoma
  • Stomach Cancer
  • T Acute Lymphoblastic Leukemia
  • T-cell Lymphoma
  • Thyroid Cancer
  • Triple-Negative Breast Cancer
  • uncategorized
  • Uterine Serous Carcinoma

You Missed

NSCLC Pancreatic cancer

Erlotinib is an EGFR TKI for NSCLC and Pancreatic Cancer Research

B-cell malignancies

Parsaclisib is an Orally Active PI3Kδ Inhibitor for B-cell Malignancies Research

Leukemia

Nilotinib is an Orally Active Bcr-Abl Tyrosine Kinase Inhibitor for CML Research

Acute Lymphoblastic Leukemia Cancer Prostate Cancer

Temsirolimus is an mTOR Inhibitor for Kinds of Cancers Research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Copyright © All rights reserved | Blogus by Themeansar.